How Phase 1 Works in Cancer Research

Part of Understanding Cancer Trials: How cancer trials are organized.

About 4 minutes. Free, in your language, no account needed.

This is general education about clinical research — not medical advice, and not a way to join a study. Talk to your own doctor about your situation.

Phase 1 in cancer research is different from phase 1 in most other areas of medicine. This lesson says how, plainly, because the difference is often not explained.

In much of medicine, phase 1 uses healthy volunteers

For many kinds of medicine, the first study in people is done in healthy volunteers. They do not have the disease. They are paid for their time, and the study is looking only at what the body does with the medicine and what side effects appear.

In cancer research, that is usually not how it works

Cancer treatments are often too toxic to give to a healthy person. It would not be acceptable to expose someone with no disease to that risk.

So cancer phase 1 studies usually enroll people who have the cancer being studied.

And in practice, they often enroll people whose cancer has continued to grow after the standard treatments, or people who cannot receive those standard treatments for some other reason. That is a plain fact about how these studies are usually built, and you deserve to hear it stated rather than discovered.

There are exceptions. Some phase 1 studies enroll people earlier in their illness. Some study treatments that are not toxic in that way. If you are ever looking at a specific study, this is something to ask about that study rather than assume.

What a phase 1 study is actually asking

The question in phase 1 is about safety and dose.

Researchers want to know how the body handles the treatment, what side effects appear, how severe they are, and what amount can be given. Often people join in small groups, with each group receiving a different amount, and the study moves forward only if the earlier groups were watched and the results reviewed.

Whether the treatment helps the cancer is not the main question at this stage. It is often measured and noted, but the study is not designed to answer it. A study is only able to answer the question it was designed and sized to answer.

Why this matters for understanding a conversation

Because of all this, a conversation about a phase 1 cancer study is a conversation that carries a lot of weight. It often happens at a difficult point. The words used can be easy to misread in both directions.

Two things are worth holding at once, and they are both true.

• A phase 1 study is early research, and its purpose is to learn about safety and dose.
• People who take part are patients receiving care, and their comfort, symptoms and dignity are still the responsibility of the team looking after them.

Neither of those facts cancels the other.

Questions that belong to your own team

This course cannot tell you what any of this means for you. What it can do is name the things that a person is entitled to have explained clearly, in words they understand, before deciding anything:

• What is this particular study designed to find out?
• What would happen at each visit, and how often?
• What is already known about the side effects, and what is not yet known?
• What would happen if I decided not to take part? What would my care be then?
• Who do I call if something changes at three in the morning?

Those questions are yours to ask, and the answers are theirs to give.

In short

• Cancer phase 1 studies usually enroll people who have the disease, not healthy volunteers, because these treatments can be too toxic for a healthy person.
• They often enroll people whose cancer has grown after standard treatments, or who cannot have those treatments. There are exceptions.
• The main question in phase 1 is safety and dose, not whether the treatment works.
• A study can only answer the question it was designed and sized to answer.
• What any of this means for you is a conversation with your own oncologist.